Cyted Health
Cyted Health believes early and accurate identification of oesophageal disease can change the clinical clock - bringing clarity sooner, so clinicians can act earlier with greater impact. The company is dedicated to improving early detection and prevention of oesophageal adenocarcinoma. Its platform combines minimally invasive cell collection with high-resolution molecular analysis to detect early biological changes associated with Barrett’s oesophagus and cancer. Cyted Health has built a robust portfolio of peer-reviewed publications and conducted over 40,000 tests using its diagnostic platform. Cyted Health cares about restoring time when medicine does its best work: clearer answers, more informed decisions, and fewer patients left waiting in anxiety, so more people can get back to life, facing forward with confidence not concern.